<DOC>
	<DOC>NCT00044902</DOC>
	<brief_summary>Epratuzumab is currently being studied in combination with rituximab, for the treatment of patients with low-grade NHL who failed previous chemotherapy and have never received rituximab or who received rituximab as a single agent or in combination with chemotherapy as their last treatment and who demonstrated a partial response or complete response for at least 12 months.</brief_summary>
	<brief_title>Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<criteria>Diagnosis of relapsed or refractory lowgrade, CD20+, Bcell NHL * Received and failed at least 1 prior regimen of chemotherapy * Rituximabnaive or received prior rituximab in their last treatment (single agent or in combination with chemotherapy) and demonstrated a time to progression of at least 12 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>